MRNA Stock Recent News

The Trump administration is reviewing a contract extended to Moderna in the final days of the Biden administration.

Moderna (MRNA -6.67%) became a hot investment during the pandemic as its COVID vaccine made investors bullish on its future. But you may be surprised to learn that now you can buy the stock around the levels it was at in April 2020 -- even before regulators approved its vaccine.

A meeting of the Food and Drug Administration's vaccine advisory committee to discuss the next season's flu vaccine has reportedly been canceled, the second such disruption of a meeting involving vaccine policy experts at the federal level since prominent vaccine skeptic Robert F. Kennedy Jr took over as the Health and Human Services secretary earlier this month.

U.S. health officials are reevaluating a $590 million contract that was awarded to Moderna for the development of its bird flu vaccine, Bloomberg News reported on Wednesday, citing sources.

SK bioscience's first mRNA vaccine candidate enters Phase 1/2 clinical trials in Australia and New Zealand, with interim results expected by 2026 Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from CEPI SK bioscience will expand its vaccine portfolio and secure global competitiveness by developing mRNA vaccines SEONGNAM, South Korea , Feb. 25, 2025 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced the commencement of global Phase 1/2 clinical trials for its mRNA-based Japanese encephalitis vaccine candidate, GBP560. SK bioscience's development of vaccine for Japanese encephalitis could not only help to protect against Japanese Encephalitis but also pave the way to the development of an mRNA technology that could be potentially adapted in a matter of weeks to develop a vaccine against a novel as-yet-identified infectious disease 'Dise

CAMBRIDGE, MA / ACCESS Newswire / February 25, 2025 / Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference, on Wednesday, March 5th at 9:10am ET Barclays 27th Annual Global Healthcare Conference, on Tuesday, March 11th at 1:30pm ET A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website. Webcast: investors.modernatx.com.

Recent in-vitro lab results confirm that the Company's proprietary Smart mRNA can be used as a potential on/off switch for selectively detecting cancer cells Recent in-vitro lab results confirm that the Company's proprietary Smart mRNA can be used as a potential on/off switch for selectively detecting cancer cells

Explore how Moderna's (MRNA) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Stocks of MRNA, PFE, NVAX and BNTX rose in anticipation that a new virus in China could trigger another pandemic.

Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.